217 related articles for article (PubMed ID: 35793473)
1. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ.
Curmin R; Guillo S; De Rycke Y; Bachelez H; Beylot-Barry M; Beneton N; Chosidow O; Dupuy A; Joly P; Jullien D; Richard MA; Viguier M; Sbidian E; Paul C; Mahé E; Tubach F;
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2101-2112. PubMed ID: 35793473
[TBL] [Abstract][Full Text] [Related]
2. Switching biologics in children with psoriasis: Results from the BiPe cohort.
Phan C; Beauchet A; Reguiai Z; Severino-Freire M; Mazereeuw-Hautier J; Bursztejn AC; Barbarot S; Hadj-Rabia S; Girard C; Phan A; Lacour JP; Lasek A; Abasq C; Brenaut E; Perrussel M; Droitcourt C; Mallet S; Piram M; Fougerousse AC; Barthélémy H; Balguérie X; Mahé E;
Pediatr Dermatol; 2022 Jan; 39(1):35-41. PubMed ID: 34888920
[TBL] [Abstract][Full Text] [Related]
3. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.
Feldman SR; Zhao Y; Navaratnam P; Friedman HS; Lu J; Tran MH
J Manag Care Spec Pharm; 2015 Mar; 21(3):201-9. PubMed ID: 25726029
[TBL] [Abstract][Full Text] [Related]
4. Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Iskandar IYK; Warren RB; Lunt M; Mason KJ; Evans I; McElhone K; Smith CH; Reynolds NJ; Ashcroft DM; Griffiths CEM;
J Invest Dermatol; 2018 Apr; 138(4):775-784. PubMed ID: 29080680
[TBL] [Abstract][Full Text] [Related]
5. Brodalumab Seems to Recover Its Therapeutic Efficacy After a Relatively Short "Washout" Period with Anti-TNF Agents: A Successful Pattern for Double-switch Therapy.
Tampouratzi E; Sfaelos K; Talaiporou K; Douvali Τ; Katsantonis J
Acta Dermatovenerol Croat; 2023 Aug; 31(1):48-50. PubMed ID: 37843093
[TBL] [Abstract][Full Text] [Related]
6. Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis.
Gooderham MJ; Lynde C; Turchin I; Avadisian M; Labelle M; Papp KA
J Dermatol; 2022 Jan; 49(1):95-105. PubMed ID: 34747071
[TBL] [Abstract][Full Text] [Related]
7. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
[TBL] [Abstract][Full Text] [Related]
8. Switching of biologics in psoriasis: Reasons and results.
Honda H; Umezawa Y; Kikuchi S; Yanaba K; Fukuchi O; Ito T; Nobeyama Y; Asahina A; Nakagawa H
J Dermatol; 2017 Sep; 44(9):1015-1019. PubMed ID: 28488283
[TBL] [Abstract][Full Text] [Related]
9. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Iskandar IYK; Ashcroft DM; Warren RB; Evans I; McElhone K; Owen CM; Burden AD; Smith CH; Reynolds NJ; Griffiths CEM
Br J Dermatol; 2017 May; 176(5):1297-1307. PubMed ID: 27589476
[TBL] [Abstract][Full Text] [Related]
10. Persistence Among Patients with Crohn Disease Previously Treated with an Anti-tumor Necrosis Factor Inhibitor and Switching or Cycling to Another Biologic Agent.
Zhdanava M; Kachroo S; Manceur AM; Ding Z; Holiday C; Zhao R; Godwin B; Pilon D
Clin Ther; 2023 Aug; 45(8):770-777. PubMed ID: 37442653
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort.
Sbidian E; Giboin C; Bachelez H; Paul C; Beylot-Barry M; Dupuy A; Viguier M; Lacour JP; Schmutz JL; Bravard P; Mahé E; Beneton N; Misery L; Delaporte E; Modiano P; Barbarot S; Regnier E; Jullien D; Richard MA; Joly P; Tubach F; Chosidow O
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):2046-2054. PubMed ID: 28609574
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
[TBL] [Abstract][Full Text] [Related]
13. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
Takahashi N; Noda S; Taniguchi T; Adachi M
Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
Bissonnette R; Kerdel F; Naldi L; Papp K; Galindo C; Langholff W; Tang KL; Szapary P; Fakharzadeh S; Srivastava B; Goyal K; Gottlieb AB
J Drugs Dermatol; 2017 Oct; 16(10):1002-1013. PubMed ID: 29036254
[TBL] [Abstract][Full Text] [Related]
15. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Dand N; Barker JN; Smith CH; Griffiths CEM;
Br J Dermatol; 2024 Apr; 190(5):689-700. PubMed ID: 38051972
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
17. Age and psoriatic arthritis are important predictors of biologic agent switch in psoriasis.
Akdogan N; Dogan S; Bostan E; Gulseren D; Yalici-Armagan B; Elcin G; Evans SE; Karaduman A; Atakan N
Expert Rev Clin Pharmacol; 2021 Dec; 14(12):1535-1541. PubMed ID: 34519227
[TBL] [Abstract][Full Text] [Related]
18. First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq.
Assan F; Tubach F; Arlegui H; Viguier M; Beylot-Barry M; Dupuy A; Beneton N; Joly P; Jullien D; Mahé E; Paul C; Richard MA; Bachelez H; Giboin C; Chosidow O; Sbidian E;
Dermatology; 2021; 237(3):338-346. PubMed ID: 33535213
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study.
Schwarz CW; Loft N; Rasmussen MK; Nissen CV; Dam TN; Ajgeiy KK; Egeberg A; Skov L
Acta Derm Venereol; 2021 Oct; 101(10):adv00579. PubMed ID: 34642768
[TBL] [Abstract][Full Text] [Related]
20. Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study.
Puig L; Carrascosa JM; Daudén E; Sulleiro S; Guisado C
J Dermatolog Treat; 2020 Jun; 31(4):344-351. PubMed ID: 30888880
[No Abstract] [Full Text] [Related]
[Next] [New Search]
